Bangkok Genomics Innovation Balance Sheet Health
Financial Health criteria checks 6/6
Bangkok Genomics Innovation has a total shareholder equity of THB524.9M and total debt of THB0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are THB591.3M and THB66.4M respectively. Bangkok Genomics Innovation's EBIT is THB46.3M making its interest coverage ratio 33.4. It has cash and short-term investments of THB395.8M.
Key information
0%
Debt to equity ratio
฿0
Debt
| Interest coverage ratio | 33.4x |
| Cash | ฿395.82m |
| Equity | ฿524.89m |
| Total liabilities | ฿66.43m |
| Total assets | ฿591.32m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: BKGI's short term assets (THB504.0M) exceed its short term liabilities (THB47.6M).
Long Term Liabilities: BKGI's short term assets (THB504.0M) exceed its long term liabilities (THB18.8M).
Debt to Equity History and Analysis
Debt Level: BKGI is debt free.
Reducing Debt: BKGI has not had any debt for past 5 years.
Debt Coverage: BKGI has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: BKGI has no debt, therefore coverage of interest payments is not a concern.